Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Humacyte announced FDA acceptance of its IND application for the Coronary Tissue Engineered Vessel (CTEV), enabling the initiation of a first-in-human Phase 2a study this quarter. The study will enroll ten adult patients to evaluate the safety and efficacy of CTEV as an off-the-shelf vascular conduit for coronary artery bypass grafting (CABG).
Key figures
- Drug Name
- CTEV
- Phase Of Trial
- Phase 2a
- Patient count
- 10
- Market size annual procedures us
- >400,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.